venerdì, 24 maggio 2024
20 Febbraio 2018

FDA expands approval of Durvalumab to reduce the risk of non-small cell lung cancer progressing

February 16, 2018 – The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of … (leggi tutto)